<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36879">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01969721</url>
  </required_header>
  <id_info>
    <org_study_id>1237.11</org_study_id>
    <secondary_id>2013-000808-41</secondary_id>
    <nct_id>NCT01969721</nct_id>
  </id_info>
  <brief_title>Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients</brief_title>
  <official_title>Randomized, Double-blind, Double-dummy, Active-controlled, 4 Period Complete Cross-over Study to Compare the Effect on Lung Function of 6 Weeks Once Daily Treatment With Orally Inhaled Tiotropium+Olodaterol Fixed Dose Combination Delivered by the Respimat® Inhaler vs. 6 Weeks Twice Daily Treatment With Fluticasone Propionate+Salmeterol Fixed Dose Combination Delivered by the Accuhaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Belgium: Federal Public Service Health, Food Chain Safety, Environment</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Denmark: The Danish Health and Medicines Authority</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Netherlands: Central Committee Research Involving Human Subjects</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to compare the lung function profile of once daily treatment
      with tiotropium+olodaterol FDC [2.5/ 5µg and 5/ 5µg] delivered by the RESPIMAT with the lung
      function profile of twice daily treatment with fluticasone propionate+salmeterol FDC
      [250/50µg and 500/50µg] delivered by the Accuhaler® after 6 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>FEV1 AUC0-12h - change from baseline after 6 weeks of treatment</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-24h - change from baseline 6-weeks of treatment.</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1- change from baseline 6-weeks of treatment.</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC 12-24 h - change from baseline 6-weeks of treatment.</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak 0-3h FEV1- change from baseline 6-weeks of treatment.</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">232</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>T+O FDC dosage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T+O FDC dosage 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICS/LABA FDC Dosage 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICS/LABA FDC Dosage 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate</intervention_name>
    <description>low dose</description>
    <arm_group_label>ICS/LABA FDC Dosage 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol</intervention_name>
    <arm_group_label>ICS/LABA FDC Dosage 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo/dummy for blinding purposes</description>
    <arm_group_label>T+O FDC dosage 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo/dummy for blinding purposes</description>
    <arm_group_label>ICS/LABA FDC Dosage 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
    <description>tiotropium high dose</description>
    <arm_group_label>T+O FDC dosage 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olodaterol</intervention_name>
    <arm_group_label>T+O FDC dosage 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olodaterol</intervention_name>
    <arm_group_label>T+O FDC dosage 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo/dummy for blinding purposes</description>
    <arm_group_label>T+O FDC dosage 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo/dummy for blinding purposes</description>
    <arm_group_label>ICS/LABA FDC Dosage 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
    <description>tiotropium low dose</description>
    <arm_group_label>T+O FDC dosage 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate</intervention_name>
    <description>low dose</description>
    <arm_group_label>ICS/LABA FDC Dosage 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol</intervention_name>
    <arm_group_label>ICS/LABA FDC Dosage 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of chronic obstructive pulmonary disease

          2. Relatively stable airway obstruction with a post-bronchodilator 30% &lt;/= Forced
             Expiratory Volume in 1 second (FEV1)&lt;80% of predicted normal and a
             post-bronchodilator FEV1/(Forced Vital Capacity)FVC &lt;70%

          3. Male or female patients, 40 years of age or older

          4. Smoking history of more than 10 pack years

          5. Ability to perform technically acceptable pulmonary function tests and maintain
             records

          6. Ability to inhale medication in a competent manner from the RESPIMAT Inhaler,
             Accuhaler and from a metered dose inhaler (MDI)

        Exclusion criteria:

          1. Significant disease other than COPD

          2. COPD exacerbation that required treatment with antibiotics, systemic steroids (oral
             or iv) or hospitalization in the last 3 months.

          3. Clinically relevant abnormal lab values

          4. History of asthma

          5. Diagnosis of thyrotoxicosis

          6. Diagnosis of paroxysmal tachycardia

          7. History of myocardial infarction

          8. Unstable or life-threatening cardiac arrhythmia

          9. Hospitalization for heart failure within the past year

         10. Known active tuberculosis

         11. malignancy for which patient has undergone resection, radiation therapy or
             chemotherapy within last five years

         12. History of life-threatening pulmonary obstruction

         13. History of cystic fibrosis

         14. Clinically evident bronchiectasis

         15. History of significant alcohol or drug abuse

         16. History of thoracotomy with pulmonary resection

         17. oral or patch ß-adrenergics

         18. Oral corticosteroid medication within 6 weeks prior to Visit 1

         19. Regular use daytime oxygen therapy for more than one hour per day

         20. Pulmonary rehabilitation program in the six weeks prior to the screening visit

         21. Investigational drug within one month or six half lives (whichever is greater) prior
             to screening visit

         22. Known hypersensitivity to ß-adrenergic drugs, BAC, EDTA

         23. Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1237.11.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyjov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rokycany</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tabor</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trebic</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.45004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kolding</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odense C</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.45003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mönchengladbach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.31005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.31006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.31007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zutphen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pozuelo de Alarcón</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>1237.11.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>October 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Salmeterol</mesh_term>
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Tiotropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
